CR8226A - Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos - Google Patents

Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos

Info

Publication number
CR8226A
CR8226A CR8226A CR8226A CR8226A CR 8226 A CR8226 A CR 8226A CR 8226 A CR8226 A CR 8226A CR 8226 A CR8226 A CR 8226A CR 8226 A CR8226 A CR 8226A
Authority
CR
Costa Rica
Prior art keywords
quinolincarbonitrilos
amino
preparation
Prior art date
Application number
CR8226A
Other languages
English (en)
Inventor
Wiggins Sutherland Karen
Brian Feigelson Greg
Harris Boschelli Diane
Michael Blum David
Lee Strong Henry
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34215972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8226(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8226A publication Critical patent/CR8226A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Materials Engineering (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
CR8226A 2003-08-19 2006-02-02 Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos CR8226A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49619103P 2003-08-19 2003-08-19

Publications (1)

Publication Number Publication Date
CR8226A true CR8226A (es) 2008-08-21

Family

ID=34215972

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8226A CR8226A (es) 2003-08-19 2006-02-02 Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos

Country Status (25)

Country Link
US (2) US7297795B2 (es)
EP (1) EP1660453A2 (es)
JP (1) JP2007502819A (es)
KR (1) KR20060066733A (es)
CN (1) CN1835923A (es)
AR (1) AR045277A1 (es)
AU (1) AU2004267061A1 (es)
BR (1) BRPI0413667A (es)
CA (1) CA2535385A1 (es)
CO (1) CO5670369A2 (es)
CR (1) CR8226A (es)
EC (1) ECSP066384A (es)
GT (1) GT200400165A (es)
IL (1) IL173456A0 (es)
MX (1) MXPA06001590A (es)
MY (1) MY140542A (es)
NO (1) NO20060539L (es)
PA (1) PA8609301A1 (es)
PE (1) PE20050344A1 (es)
RU (1) RU2345069C2 (es)
SA (1) SA04250258B1 (es)
SG (1) SG145744A1 (es)
SV (1) SV2005001855A (es)
TW (1) TW200517378A (es)
WO (1) WO2005019201A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7479561B2 (en) * 2004-08-16 2009-01-20 Wyeth 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
AU2006247520A1 (en) * 2005-05-18 2006-11-23 Wyeth 3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same
RU2007140957A (ru) * 2005-05-25 2009-06-27 Вайет (Us) Способы синтеза производных 6-алкиламинохинолинов
CN101203494A (zh) * 2005-05-25 2008-06-18 惠氏公司 合成经取代3-氰基喹啉和其中间物的方法
WO2006127205A2 (en) * 2005-05-25 2006-11-30 Wyeth Methods of preparing 3-cyano-quinolines and intermediates made thereby
WO2007005462A1 (en) 2005-07-01 2007-01-11 Wyeth Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
WO2007092153A2 (en) * 2006-02-08 2007-08-16 Wyeth Preparation of 7-alkenyl-3 quinolinecarbonitriles via a palladium mediated coupling reaction
CN101195578B (zh) * 2006-12-08 2012-04-25 上海睿智化学研究有限公司 1-(卤烷氧基)-2-烷氧基-5-硝基苯类化合物的合成方法
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
EP3175853B1 (en) 2008-08-04 2023-11-01 Wyeth LLC Antineoplastic combinations of neratinib and capecitabine
WO2010030835A2 (en) * 2008-09-11 2010-03-18 Wyeth Llc Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor
PT3000467T (pt) 2009-04-06 2023-03-30 Wyeth Llc Regime de tratamento utilizando neratinib para o cancro de mama
CA2766067A1 (en) 2009-07-02 2011-01-06 Wyeth Llc 3-cyanoquinoline tablet formulations and uses thereof
CN101792416B (zh) * 2010-01-15 2011-10-05 南京医科大学 一种博舒替尼的制备工艺
ES2622138T3 (es) * 2010-06-23 2017-07-05 Hanmi Science Co., Ltd. Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
CN102952037A (zh) * 2012-11-18 2013-03-06 大连九信生物化工科技有限公司 一种2-氰基-n-(2,4-二氯-5-甲氧苯基)乙酰胺的合成方法
IN2014CH00840A (es) 2014-02-20 2015-09-18 Apotex Inc
CN104876865A (zh) * 2014-02-27 2015-09-02 南京正荣医药化学有限公司 一种博舒替尼的制备工艺
MX2017017124A (es) 2015-07-06 2018-03-09 Gilead Sciences Inc 6-amino-quinolin-3-carbonitrilos como moduladores de cancer osaka tiroides (cot).
ES2734713T3 (es) 2015-07-06 2019-12-11 Gilead Sciences Inc Moduladores Cot y métodos de utilización de los mismos
CN105085398A (zh) * 2015-09-06 2015-11-25 合肥华方医药科技有限公司 一种博舒替尼异构体杂质的制备方法
CN105646345A (zh) * 2016-03-16 2016-06-08 浙江海正药业股份有限公司 博舒替尼的新晶型及其制备方法
JP6776378B2 (ja) 2016-06-30 2020-10-28 ギリアード サイエンシーズ, インコーポレイテッド Cotモジュレーターとしての4,6−ジアミノキナゾリン類およびその使用方法
WO2019076316A1 (zh) * 2017-10-18 2019-04-25 江苏恒瑞医药股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
CN108084085B (zh) * 2017-12-28 2019-11-26 山东铂源药业有限公司 一种n-(3-氯-4-(2-吡啶甲氧基)苯基)-2-氰基乙酰胺的制备方法
WO2019186429A1 (en) * 2018-03-30 2019-10-03 Sun Pharmaceutical Industries Limited A process for the preparation of bosutinib
CN109180578B (zh) * 2018-10-19 2020-06-26 山东创新药物研发有限公司 一种博舒替尼的制备方法
CN111646939A (zh) * 2019-03-04 2020-09-11 鲁南制药集团股份有限公司 一种博舒替尼的制备方法
CN111646955B (zh) * 2019-03-04 2024-05-24 鲁南制药集团股份有限公司 一种制备博舒替尼中间体的方法
TWI915558B (zh) 2019-06-14 2026-02-21 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CA3175541A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
EP4126862B1 (en) 2020-04-02 2025-05-21 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція

Also Published As

Publication number Publication date
PE20050344A1 (es) 2005-06-19
TW200517378A (en) 2005-06-01
JP2007502819A (ja) 2007-02-15
WO2005019201A3 (en) 2005-08-04
US7297795B2 (en) 2007-11-20
BRPI0413667A (pt) 2006-10-24
MXPA06001590A (es) 2006-05-19
NO20060539L (no) 2006-02-13
KR20060066733A (ko) 2006-06-16
GT200400165A (es) 2005-04-12
MY140542A (en) 2009-12-31
AR045277A1 (es) 2005-10-19
CN1835923A (zh) 2006-09-20
CO5670369A2 (es) 2006-08-31
EP1660453A2 (en) 2006-05-31
AU2004267061A1 (en) 2005-03-03
CA2535385A1 (en) 2005-03-03
US20080033175A1 (en) 2008-02-07
PA8609301A1 (es) 2005-03-03
RU2345069C2 (ru) 2009-01-27
SG145744A1 (en) 2008-09-29
IL173456A0 (en) 2006-06-11
RU2006108524A (ru) 2007-09-27
US20050043537A1 (en) 2005-02-24
WO2005019201A2 (en) 2005-03-03
ECSP066384A (es) 2006-08-30
SA04250258B1 (ar) 2009-01-07
SV2005001855A (es) 2005-11-04

Similar Documents

Publication Publication Date Title
EP1591438A4 (en) PROCESS FOR THE PREPARATION OF 4-AMINODIPHENYLAMINE
NO20070753L (no) Fremgangsmåte for fremstilling av dihydropteridinoner
IL173456A0 (en) Process for the preparation of 4-amino-3-quinolinecarbonitriles
DK1611108T3 (da) Fremgangsmåde til fremstilling af telmisartan
DK1546122T3 (da) Fremgangsmåde til fremstilling af valsartan
FI20030383A0 (fi) Menetelmä katalyytin valmistamiseksi
MA26407A1 (fr) Procede de preparation de combretastatines
ITMI20031994A1 (it) Procedimento per la preparazione di fludarabina fosfato
EP1682627A4 (en) Process for preparing methyllithium
ITMI20030346A1 (it) Procedimento per la produzione di mesitilene.
ITMI20041920A1 (it) Processo per la preparazione di n, n-diisopropil-3-2-idrossi-5-metilfenil-3-fenil-propabammina
ITMI20030018A1 (it) Procedimento per la preparazione di composti mono-
ITMI20041941A1 (it) Processo per la preparazione di lisofosfatidilcoline
EP1477477A4 (en) PROCESS FOR THE PREPARATION OF CAROTENOIDS
ITMI20040452A1 (it) Processo per la preparazione di oxcarbazepina
ITMI20030019A1 (it) Procedimento per la preparazione di composti mono-
CL2004001156A1 (es) Procedimiento de preparacion de compuestos heterociclicos.
ITMI20041086A1 (it) Procedimento per la preparazione di idrocarbilalogenuri
ITVR20030088A1 (it) Procedimento per la realizzazione di fasce anti-implosione per cinescopi
DK1685097T3 (da) Fremgangsmåde til fremstilling af 4-pentafluorsulfanylbenzoylguanidiner
ITMI20052464A1 (it) Procedimento per la preparazi9one di norelgestromin norelgestromina
AR028111A1 (es) Procedimiento para la produccion de isocianatos
ES1058015Y (es) Maquina para la fabricacion de elementos de escayola
FR2835839B1 (fr) Procede de preparation de la 7beta-hydroxy-dehydroepiandrosterone
ITMI20040003A1 (it) Processo per la preparazione di 6-fluoro-2-metil-1-indanone

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)